Home › Asset managers › Gabelli › 2025-2026 › Against the board
Two kinds of vote are listed: a board-sponsored proposal Gabelli voted AGAINST or withheld on, and a shareholder proposal it voted FOR. One row is one proposal at one meeting; “funds” is how many of the manager’s funds or accounts voted that way.
Everything Only shareholder proposals it backed
490 proposals.
| Company | Meeting | Proposal | Category | On the ballot from | Gabelli voted | Funds |
|---|---|---|---|---|---|---|
| DANAHER CORPORATION | 2026-05-05 | To approve the Company's Amended and Restated Omnibus Incentive Plan. | Compensation | Board | AGAINST | 1 |
| DATANG INTERNATIONAL POWER GENERATION CO LTD | 2025-12-30 | TO CONSIDER AND APPROVE THE RESOLUTION ON THE FINANCING PROPOSAL OF DATANG POWER AS THE PARENT COMPANY FOR THE YEAR 2026 | Capital Structure | Board | ABSTAIN | 1 |
| DBV TECHNOLOGIES S.A. | 2026-06-03 | Advisory opinion on the compensation of named executive officers other than the Chief Executive Officer | Say-on-Pay | Board | ABSTAIN | 1 |
| DBV TECHNOLOGIES S.A. | 2026-06-03 | Allocation of income for the year ended December 31, 2025 | Capital Structure | Board | ABSTAIN | 1 |
| DBV TECHNOLOGIES S.A. | 2026-06-03 | Allocation of the accumulated deficit to the ''Additional paid-in capital'' | Capital Structure | Board | ABSTAIN | 1 |
| DBV TECHNOLOGIES S.A. | 2026-06-03 | Approval of the compensation policy for the Chairman of the Board of Directors for the year ending December 31, 2026 | Compensation | Board | ABSTAIN | 1 |
| DBV TECHNOLOGIES S.A. | 2026-06-03 | Approval of the compensation policy for the Chief Executive Officer and Deputy Chief Executive Officer for the year ending December 31, 2026 | Compensation | Board | ABSTAIN | 1 |
| DBV TECHNOLOGIES S.A. | 2026-06-03 | Approval of the compensation policy for the Directors for the year ending December 31, 2026 | Compensation | Board | ABSTAIN | 1 |
| DBV TECHNOLOGIES S.A. | 2026-06-03 | Approval of the fixed, variable and non-recurring components of overall compensation and benefits of all types paid or assigned during the year ended December 31, 2025, to Mr. Michel de Rosen, Chairman of the Board of Directors | Compensation | Board | ABSTAIN | 1 |
| DBV TECHNOLOGIES S.A. | 2026-06-03 | Approval of the fixed, variable and non-recurring components ofoverall compensation and benefits of all types paid or assignedduring the year ended December 31, 2025, to Mr. Daniel Tasse,Chief Executive Officer | Compensation | Board | ABSTAIN | 1 |
| DBV TECHNOLOGIES S.A. | 2026-06-03 | Approval of the information set out in section I of Article L.22-10-9 of the French Commercial Code on the compensation of corporate officers for the year ended December 31, 2025 | Compensation | Board | ABSTAIN | 1 |
| DBV TECHNOLOGIES S.A. | 2026-06-03 | Authorization to be granted to the Board of Directors to allocate for free existing and/or to be issued shares to employees and/or certain corporate officers of the Company or related companies or economic interest groups | Capital Structure | Board | ABSTAIN | 1 |
| DBV TECHNOLOGIES S.A. | 2026-06-03 | Authorization to be granted to the Board of Directors to buy back company shares on the Company's behalf pursuant to Article L.22- 10-62 of the French Commercial Code | Capital Structure | Board | ABSTAIN | 1 |
| DBV TECHNOLOGIES S.A. | 2026-06-03 | Authorization to be granted to the Board of Directors to grant stock options to employees and/or certain officers of the Company or related companies or economic interest groups | Compensation | Board | ABSTAIN | 1 |
| DBV TECHNOLOGIES S.A. | 2026-06-03 | Delegation of authority to be granted to the Board of Directors to decide on any merger-absorption, spin-off or partial contribution of assets | Extraordinary Transactions | Board | ABSTAIN | 1 |
| DBV TECHNOLOGIES S.A. | 2026-06-03 | Delegation of authority to be granted to the Board of Directors to decide on the issue of ordinary shares to be issued immediately or in the future by the Company, without preferential subscription rights in favor of a category of persons satisfying determined characteristics within the framework of an equity financing agreement on the United States stock market known as ''At-The- Market'' or ''ATM Program'' | Capital Structure | Board | ABSTAIN | 1 |
| DBV TECHNOLOGIES S.A. | 2026-06-03 | Delegation of authority to be granted to the Board of Directors to increase the number of securities to be issued in the event of a capital increase with or without preferential subscription rights, in the event of excess demand | Capital Structure | Board | ABSTAIN | 1 |
| DBV TECHNOLOGIES S.A. | 2026-06-03 | Delegation of authority to be granted to the Board of Directors to issue ordinary shares and/or equity securities giving access to other equity securities or to the allocation of debt securities and/or securities giving access to ordinary shares with preferential subscription rights | Capital Structure | Board | ABSTAIN | 1 |
| DBV TECHNOLOGIES S.A. | 2026-06-03 | Delegation of authority to be granted to the Board of Directors to issue warrants (BSA), subscription and/or acquisition of new and/or existing warrants (BSAANE) and/or subscription and/or acquisition of new and/or existing redeemable warrants (BSAAR) without preferential subscription rights in favor of a category of persons | Capital Structure | Board | ABSTAIN | 1 |
| DBV TECHNOLOGIES S.A. | 2026-06-03 | Delegation of powers to be granted to the Board of Directors to issue ordinary shares and/or equity securities giving access to other equity securities or to the allocation of debt securities and/or securities giving access to ordinary shares, without preferential subscription rights in favor of one or more persons specifically designated by the Board of Directors | Capital Structure | Board | ABSTAIN | 1 |
| DBV TECHNOLOGIES S.A. | 2026-06-03 | Delegation to be granted to the Board of Directors to increase the share capital by issuance of ordinary shares and/or securities giving access to the share capital within the limits set by the applicable legal and regulatory provisions on the date of the capital increase in consideration for contributions in kind of securities or securities giving access to the share capital | Capital Structure | Board | ABSTAIN | 1 |
| DBV TECHNOLOGIES S.A. | 2026-06-03 | Delegation to be granted to the Board of Directors to reduce the share capital by cancellation of shares pursuant to Article L.22-10- 62 of the French Commercial Code | Capital Structure | Board | ABSTAIN | 1 |
| DBV TECHNOLOGIES S.A. | 2026-06-03 | Increase of the total remuneration (annual budget) allocated to Directors | Compensation | Board | ABSTAIN | 1 |
| DBV TECHNOLOGIES S.A. | 2026-06-03 | Overall limit on the maximum authorized amounts set under the resolutions thirty-fifth and thirty-sixth | Capital Structure | Board | ABSTAIN | 1 |
| DBV TECHNOLOGIES S.A. | 2026-06-03 | Overall limit on the maximum authorized amounts set under the resolutions twenty-second, twenty-third, twenty-fourth, twenty-fifth, twenty-sixth, twenty-eighth and thirtieth resolutions | Capital Structure | Board | ABSTAIN | 1 |
| DBV TECHNOLOGIES S.A. | 2026-06-03 | Please refer below and to the other side of the card for a description of the matters submitted at the Annual General Meeting. | Director Elections | Board | ABSTAIN | 1 |
| DBV TECHNOLOGIES S.A. | 2026-06-03 | Renewal of the term of office of KPMG, as statutory auditor | Audit-related | Board | ABSTAIN | 1 |
| DENTSPLY SIRONA INC. | 2026-06-02 | Approval of Amendment No. 2 to the 2024 Omnibus Incentive Plan to increase the number of shares of the Company's Common Stock issuable under such Plan. | Compensation | Board | AGAINST | 1 |
| DIAGEO PLC | 2025-11-06 | DISAPPLICATION OF PRE-EMPTION RIGHTS | Capital Structure | Board | ABSTAIN | 1 |
| EATON CORPORATION PLC | 2026-04-22 | Approving the appointment of Ernst & Young LLP as Independent auditor for 2026 and authorizing the Audit Committee of the Board of Directors to set auditor remuneration. | Audit-related | Board | AGAINST | 1 |
| ELI LILLY AND COMPANY | 2026-05-04 | Ratification of the appointment of Ernst & Young LLP as the independent auditor for 2026. | Audit-related | Board | AGAINST | 1 |
| EMERA INC | 2026-05-21 | AMEND STOCK OPTION PLAN | Compensation | Board | ABSTAIN | 1 |
| EMERGENT BIOSOLUTIONS INC. | 2026-04-29 | To approve an amendment to the Emergent BioSolutions Inc. Amended and Restated Stock Incentive Plan to increase the number of shares of common stock for the grant of awards under the plan. | Compensation | Board | ABSTAIN | 1 |
| ENGIE | 2026-04-29 | Delegation of authority to the Board of Directors to increase the number of shares to be issued in the event of a capital increase. with or without preferential subscription rights for shareholders. | Capital Structure | Board | ABSTAIN | 1 |
| ENI S.P.A | 2026-05-06 | Appointment of the Director: Slate proposed by the Shareholder Italian Ministry of the Economy and Finance. | Director Elections | Board | ABSTAIN | 1 |
| ENI S.P.A | 2026-05-06 | Appointment of the Director: Slate proposed by the Shareholder Romano Minozzi and his subsidiaries. | Director Elections | Board | ABSTAIN | 1 |
| ENI S.P.A | 2026-05-06 | Appointment of the Statutory Auditors: Slate proposed by a group of Shareholders composed of asset management companies and other Institutional Investors | Audit-related | Board | ABSTAIN | 1 |
| ENI S.P.A | 2026-05-06 | Long term incentive Plan 2026-2028 and disposal of Eni treasury shares to serve the Plan. | Compensation | Board | ABSTAIN | 1 |
| FEDEX CORPORATION | 2025-09-29 | Ratify the appointment of Ernst & Young LLP as FedEx's independent registered public accounting firm for fiscal year 2026. | Audit-related | Board | AGAINST | 1 |
| FEVERTREE DRINKS PLC | 2026-06-09 | AUTHORISE ISSUE OF EQUITY WITHOUT PRE-EMPTIVE RIGHTS | Capital Structure | Board | ABSTAIN | 1 |
| FIRST MAJESTIC SILVER CORP. | 2026-06-10 | Say on Pay Advisory Vote BE IT RESOLVED as an ordinary resolution, on an advisory basis and not to diminish the role and responsibilities of the board of directors, that the shareholders accept the approach to executive compensation disclosed in the Company's Information Circular for this meeting. | Say-on-Pay | Board | AGAINST | 1 |
| FLUENCE ENERGY, INC. | 2026-03-12 | To approve the amendment and restatement of the Company's 2021 Incentive Award Plan. | Compensation | Board | ABSTAIN | 1 |
| GENTHERM INCORPORATED | 2026-05-14 | Approval of the Amendment to the Gentherm Incorporated 2023 Equity Incentive Plan. | Compensation | Board | ABSTAIN | 1 |
| GILEAD SCIENCES, INC. | 2026-04-30 | To approve the amended and restated Gilead Sciences, Inc. 2022 Equity Incentive Plan. | Compensation | Board | AGAINST | 1 |
| GMO INTERNET GROUP,INC. | 2026-03-19 | Appoint a Director who is not Audit and Supervisory Committee Member Kumagai, Masatoshi | Director Elections | Board | AGAINST | 1 |
| GSK PLC | 2026-05-06 | To disapply pre-emption rights - general power (special resolution) | Capital Structure | Board | ABSTAIN | 1 |
| HALEON PLC | 2026-04-29 | GENERAL AUTHORITY TO DISAPPLY PRE-EMPTION RIGHTS | Capital Structure | Board | ABSTAIN | 1 |
| HALEON PLC | 2026-04-29 | General authority to disapply pre-emption rights (Special Resolution) | Capital Structure | Board | ABSTAIN | 1 |
| HARVARD BIOSCIENCE, INC. | 2026-06-02 | Adoption and approval of an amendment to the Harvard Bioscience, Inc. 2021 Incentive Plan to increase the number of authorized shares of common stock available for issuance by 400,000 shares of common stock. | Compensation | Board | ABSTAIN | 1 |
| HCA HEALTHCARE, INC. | 2026-04-23 | To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2026. | Audit-related | Board | AGAINST | 1 |
| HEALTHEQUITY, INC. | 2026-06-25 | To approve the Amended and Restated HealthEquity, Inc. 2024 Equity Incentive Plan. | Compensation | Board | ABSTAIN | 1 |
| HILLTOP HOLDINGS INC. | 2025-07-24 | Non-binding advisory vote to approve executive compensation. | Say-on-Pay | Board | AGAINST | 1 |
| HUBSPOT, INC. | 2026-06-15 | Approve an amendment to the Company's 2024 Stock Option and Incentive Plan; | Compensation | Board | AGAINST | 1 |
| ILIKA PLC | 2025-09-23 | AUTHORISE ISSUE OF EQUITY WITHOUT PRE-EMPTIVE RIGHTS | Capital Structure | Board | ABSTAIN | 1 |
| INFORMA PLC | 2026-06-18 | AUTHORISE ISSUE OF EQUITY WITHOUT PRE-EMPTIVE RIGHTS | Capital Structure | Board | ABSTAIN | 1 |
| INGLES MARKETS, INCORPORATED | 2026-04-30 | COMPANY NOMINEE OPPOSED BY SUMMER ROAD: Rebekah Lowe | Director Elections | Board | ABSTAIN | 1 |
| INNOVATE CORP. | 2026-06-11 | To approve an amendment to the Company's Second Amended and Restated 2014 Omnibus Equity Award Plan, as amended, to increase the number of shares of Common Stock of the Company available for issuance thereunder (the "Second A&R 2014 Plan Proposal"). | Compensation | Board | ABSTAIN | 1 |
| INSPIRE MEDICAL SYSTEMS, INC. | 2026-04-30 | Approval of an amendment and restatement of the Inspire Medical Systems, Inc. 2018 Incentive Award Plan. | Compensation | Board | ABSTAIN | 1 |
| INTEL CORPORATION | 2026-05-13 | Approval of amendment and restatement of the 2006 Equity Incentive Plan. | Compensation | Board | AGAINST | 1 |
| INTERCONTINENTAL EXCHANGE, INC. | 2026-05-15 | To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. | Audit-related | Board | AGAINST | 1 |
| INTERNATIONAL BUSINESS MACHINES CORP. | 2026-04-28 | Advisory Vote on Executive Compensation | Say-on-Pay | Board | AGAINST | 1 |
| INTERNATIONAL BUSINESS MACHINES CORP. | 2026-04-28 | Ratification of Appointment of Independent Registered Public Accounting Firm | Audit-related | Board | AGAINST | 1 |
| IONIS PHARMACEUTICALS, INC. | 2026-06-04 | To approve an amendment of the Amended and Restated Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 9,500,000 shares to an aggregate of 52,000,000 shares. | Compensation | Board | ABSTAIN | 1 |
| JAMES HARDIE INDUSTRIES PLC | 2025-10-29 | Election of Director: Gary Hendrickson | Director Elections | Board | AGAINST | 1 |
| JAMES HARDIE INDUSTRIES PLC | 2025-10-29 | Election of Director: Howard Heckes | Director Elections | Board | AGAINST | 1 |
| JAMES HARDIE INDUSTRIES PLC | 2025-10-29 | Grant of Return on Capital Employed Restricted Stock Units to CEO | Capital Structure | Board | AGAINST | 1 |
| JAMES HARDIE INDUSTRIES PLC | 2025-10-29 | Increase Non-Executive Director Fee Pool | Compensation | Board | AGAINST | 1 |
| JAMES HARDIE INDUSTRIES PLC | 2025-10-29 | Re-election of Director: Anne Lloyd | Director Elections | Board | AGAINST | 1 |
| JAMES HARDIE INDUSTRIES PLC | 2025-10-29 | Re-election of Director: Peter John Davis | Director Elections | Board | AGAINST | 1 |
| JAMES HARDIE INDUSTRIES PLC | 2025-10-29 | Re-election of Director: Rada Rodriguez | Director Elections | Board | AGAINST | 1 |
| JAMES HARDIE INDUSTRIES PLC | 2025-10-29 | To receive and consider the remuneration report for fiscal year 2025 | Say-on-Pay | Board | AGAINST | 1 |
| JAMES HARDIE INDUSTRIES PLC | 2025-10-29 | To receive and consider the remuneration report for fiscal year 2025 | Say-on-Pay | Board | AGAINST | 1 |
| KIMBERLY-CLARK CORPORATION | 2026-05-14 | Ratification of Auditor | Audit-related | Board | AGAINST | 1 |
| KONINKLIJKE PHILIPS N.V. | 2026-05-08 | Authorization of the Board of Management to (i) issue shares or grant rights to acquire shares and (ii) restrict or exclude pre- emption rights: Proposal to authorize the Board of Management for a period of 18 months, effective May 8, 2026, as the body which is authorized, with the approval of the Supervisory Board, to issue shares or grant rights to acquire shares within the limits laid down in the Articles of Association | Capital Structure | Board | ABSTAIN | 1 |
| KOPIN CORPORATION | 2026-05-21 | Proposal to approve the amendment and restatement of the Kopin Corporation 2020 Equity Incentive Plan. | Compensation | Board | ABSTAIN | 1 |
| KRISPY KREME, INC. | 2026-06-10 | To approve the Amendment and Restatement of the Krispy Kreme, Inc. 2021 Omnibus Incentive Plan; | Compensation | Board | AGAINST | 1 |
| LAMAR ADVERTISING COMPANY | 2026-05-14 | Approval of an amendment and restatement of the Company's 2019 Employee Stock Purchase Plan. | Capital Structure | Board | ABSTAIN | 1 |
| LANTHEUS HOLDINGS, INC. | 2026-04-30 | The approval of the Lantheus Holdings, Inc. Amended and Restated 2026 Equity Incentive Plan. | Compensation | Board | ABSTAIN | 1 |
| LENNAR CORPORATION | 2026-04-08 | Ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending November 30, 2026. | Audit-related | Board | AGAINST | 1 |
| LIFECORE BIOMEDICAL, INC. | 2026-06-04 | To approve the Lifecore Biomedical, Inc. 2026 Stock Incentive Plan. | Compensation | Board | AGAINST | 1 |
| LIFETIME BRANDS, INC. | 2026-06-18 | TO APPROVE AN AMENDMENT AND RESTATEMENT OF THE COMPANY'S AMENDED AND RESTATED 2000 LONG-TERM INCENTIVE PLAN. | Compensation | Board | AGAINST | 1 |
| LIFEWAY FOODS, INC. | 2025-12-29 | COMPANY NOMINEES: Dorri McWhorter | Director Elections | Board | ABSTAIN | 1 |
| LIFEWAY FOODS, INC. | 2025-12-29 | COMPANY NOMINEES: Jason Scher | Director Elections | Board | ABSTAIN | 1 |
| LIFEWAY FOODS, INC. | 2025-12-29 | OPPOSITION NOMINEES: George Sent | Director Elections | Board | ABSTAIN | 1 |
| LIFEWAY FOODS, INC. | 2025-12-29 | OPPOSITION NOMINEES: Edward Smolyansky | Director Elections | Board | ABSTAIN | 1 |
| LIFEWAY FOODS, INC. | 2026-06-17 | To elect Jason Scher to serve as a member of the Board until the 2027 Annual Meeting of Shareholders (or until successors are elected and qualified). Jason Scher | Director Elections | Board | AGAINST | 1 |
| LIONSGATE STUDIOS CORP. | 2026-03-17 | Election of Directors: Emily Fine | Director Elections | Board | ABSTAIN | 1 |
| LIONSGATE STUDIOS CORP. | 2026-03-17 | Election of Directors: Richard Rosenblatt | Director Elections | Board | ABSTAIN | 1 |
| LIONSGATE STUDIOS CORP. | 2026-03-17 | Election of Directors: Yvette Ostolaza | Director Elections | Board | ABSTAIN | 1 |
| MADRIGAL PHARMACEUTICALS INC. | 2026-06-17 | Approval of Madrigal Pharmaceuticals, Inc. 2026 Stock Plan | Compensation | Board | AGAINST | 1 |
| MARINEMAX, INC. | 2026-03-03 | To approve the amendment of our 2021 Stock-Based Compensation Plan to increase the number of shares available for issuance by 415,000 shares. | Compensation | Board | ABSTAIN | 1 |
| MASTERCARD INCORPORATED | 2026-06-16 | Ratification of the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for Mastercard for 2026 | Audit-related | Board | AGAINST | 1 |
| MATTEL, INC. | 2026-05-28 | Approval of the Mattel, Inc. Amended and Restated 2010 Equity and Long-Term Compensation Plan. | Compensation | Board | AGAINST | 1 |
| MEDALLION FINANCIAL CORP. | 2026-06-09 | Proposal to approve a non-binding advisory resolution to approve the 2025 compensation of Medallion Financial Corp.'s named executive officers, as described in the proxy statement. | Say-on-Pay | Board | ABSTAIN | 1 |
| MEDIACO HOLDING INC. | 2025-08-08 | Approval of the 2025 Equity Compensation Plan as set forth in Exhibit A to the proxy statement. | Compensation | Board | ABSTAIN | 1 |
| MEDTRONIC PLC | 2025-10-16 | Renewing the Board of Directors' authority to opt out of pre- emption rights under Irish law; | Capital Structure | Board | AGAINST | 1 |
| MERCK & CO., INC. | 2026-05-26 | Ratification of the appointment of the Company's independent registered public accounting firm for 2026. | Audit-related | Board | AGAINST | 1 |
| MGM CHINA HOLDINGS LTD | 2026-05-14 | TO ADD THE TOTAL NUMBER OF THE SHARES WHICH ARE REPURCHASED UNDER THE GENERAL MANDATE IN RESOLUTION (6) TO THE TOTAL NUMBER OF THE SHARES WHICH MAY BE ISSUED UNDER THE GENERAL MANDATE IN RESOLUTION (5) | Capital Structure | Board | AGAINST | 1 |
| MGM CHINA HOLDINGS LTD | 2026-05-14 | TO GRANT A GENERAL MANDATE TO THE DIRECTORS TO ISSUE, ALLOT AND DEAL WITH ADDITIONAL SHARES (INCLUDING ANY SALE OR TRANSFER OF TREASURY SHARES OUT OF TREASURY) OF THE COMPANY NOT EXCEEDING 20% OF THE TOTAL NUMBER OF ISSUED SHARES (EXCLUDING ANY TREASURY SHARES) AT THE DATE OF PASSING THIS RESOLUTION | Capital Structure | Board | AGAINST | 1 |
| MICROSOFT CORPORATION | 2025-12-05 | Ratification of the Selection of Deloitte & Touche LLP as our Independent Auditor for Fiscal Year 2026 | Audit-related | Board | AGAINST | 1 |
← Previous Page 4 of 5 Next →
← Back to Gabelli 2025-2026 overview
Built 2026-10-04 from SEC Form N-PX filings.